 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Tuesday, September 26, 2006
Fampridine...UPDATE 3: Bloomberg....MORE
...Fampridine has been shown to improve communication between damaged nerves. Existing MS drugs either relieve symptoms such as pain or slow the disease's progression.....
Acorda hasn't decided what the drug would cost. The company wants to position Fampridine-SR in the market between symptom- relief therapies, which cost patients as much as $4,500 a year, and treatments that slow progression at a cost of $10,000 to $20,000 annually, Chief Operating Officer Mary Fisher said during the conference call.
Acorda, established in 1995, has one product on the market, the Zanaflex drug to help manage stiffness and muscle spasms in patients with multiple sclerosis or spinal-cord injuries, according to the company's Web site.
...Fampridine has been shown to improve communication between damaged nerves. Existing MS drugs either relieve symptoms such as pain or slow the disease's progression.....
Acorda hasn't decided what the drug would cost. The company wants to position Fampridine-SR in the market between symptom- relief therapies, which cost patients as much as $4,500 a year, and treatments that slow progression at a cost of $10,000 to $20,000 annually, Chief Operating Officer Mary Fisher said during the conference call.
Acorda, established in 1995, has one product on the market, the Zanaflex drug to help manage stiffness and muscle spasms in patients with multiple sclerosis or spinal-cord injuries, according to the company's Web site.